What is the first line treatment for systemic juvenile idiopathic arthritis?

What is the first line treatment for systemic juvenile idiopathic arthritis?

• A. Glucocorticoids
• B. NSAIDs
• C. DMARDs
• D. Biologic agents

Answer: (B)

In the management of systemic juvenile idiopathic arthritis (sJIA), nonsteroidal anti-inflammatory drugs (NSAIDs) are considered the first-line treatment option. NSAIDs are utilized as they help in alleviating pain and reducing inflammation in the joints and systemic symptoms. This class of medication is effective in treating the fever and arthritis associated with sJIA, and they are generally well tolerated. While glucocorticoids, disease-modifying antirheumatic drugs (DMARDs), and biologic agents can also be utilized in the management of sJIA, they are typically reserved for cases that do not respond adequately to NSAIDs or when the disease is more severe. Glucocorticoids may be used for acute exacerbations or when symptoms are particularly difficult to control, and DMARDs, like methotrexate, come into play for long-term management, particularly in chronic cases. Biologic agents are strikingly effective for sJIA but are generally indicated after NSAIDs and other therapies have not provided sufficient relief or control of the disease. Thus, NSAIDs serve as the foundational treatment in the early stages of management for this condition.

In the management of systemic juvenile idiopathic arthritis (sJIA), nonsteroidal anti-inflammatory drugs (NSAIDs) are considered the first-line treatment option. NSAIDs are utilized as they help in alleviating pain and reducing inflammation in the joints and systemic symptoms. This class of medication is effective in treating the fever and arthritis associated with sJIA, and they are generally well tolerated.

While glucocorticoids, disease-modifying antirheumatic drugs (DMARDs), and biologic agents can also be utilized in the management of sJIA, they are typically reserved for cases that do not respond adequately to NSAIDs or when the disease is more severe. Glucocorticoids may be used for acute exacerbations or when symptoms are particularly difficult to control, and DMARDs, like methotrexate, come into play for long-term management, particularly in chronic cases. Biologic agents are strikingly effective for sJIA but are generally indicated after NSAIDs and other therapies have not provided sufficient relief or control of the disease. Thus, NSAIDs serve as the foundational treatment in the early stages of management for this condition.